An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation

New England Journal of Medicine

Volumn 335, Issue 8, 1996, Pages 540-546

  Hylek, Elaine M ^a   Skates, Steven J ^a   Sheehan, Mary A ^a   Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; WARFARIN;

EID: 0029741822     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608223350802     Document Type: Article

References (30)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
2. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
3. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-9.
4. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527-39.
5. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
6. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12. [Erratum, N Engl J Med 1993;328:148.]
7. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57. [Erratum, Arch Intern Med 1994;154:2254.]
9. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52.
10. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
11. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118:511-20.
12. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
13. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108:Suppl:231S-246S.
14. International classification of diseases, 9th rev., clinical modification: ICD.9.CM. New York: McGraw-Hill, 1996.
15. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
16. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning, 1982:299.
17. Mehta CR, Patel NR, Gray R. Computing an exact confidence interval for the common odds ratio in several 2×2 contingency tables. J Am Stat Assoc 1985;80:969-73.
18. S-PLUS reference manual, version 3.2. Seattle: StatSci, 1993.
19. Logistic regression for matched case-control studies. In: Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989: 187-215.
20. Bern MM, Bothe A Jr, Bistrian B, Champagne CD, Keane MS, Blackburn GL. Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 1986;99:216-21.
21. Poller L, McKernan A, Thompson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warferin: a new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987;295:1309-12.
22. Atrial Fibrillation, Aspirin, and Anticoagulant Therapy (AFASAK 2). In: Major ongoing stroke trials. Stroke 1995;26:1978.
23. Stroke Prevention in Atrial Fibrillation (SPAF) III Study. In: Major ongoing stroke trials. Stroke 1995;26:1981.
24. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
25. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA 1988;259:1025-9.
26. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993;269:232-6.
27. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
28. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155:2185-9.
29. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-45.
30. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995;108:Suppl:352S-359S.